GKOS (Glaukos) Accounts Payable & Accrued Expense: $81.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GKOS Glaukos Corp GKOS
77 GF Score
Price $180.35
GF Value $151.01
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Glaukos Accounts Payable & Accrued Expense?

Glaukos GKOS +0.46% 77 Accounts Payable & Accrued Expense is $81.0 Mil as of Jun. 2026. GuruFocus rates GKOS with a GF Score™ of 77/100 and a GF Value™ of $151.01 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Glaukos's quarterly accounts payable & accrued expense increased from Dec. 2025 ($73.1 Mil) to Mar. 2026 ($75.7 Mil) and increased from Mar. 2026 ($75.7 Mil) to Jun. 2026 ($81.0 Mil).

Glaukos's annual accounts payable & accrued expense declined from Dec. 2023 ($53.4 Mil) to Dec. 2024 ($50.3 Mil) but then increased from Dec. 2024 ($50.3 Mil) to Dec. 2025 ($73.1 Mil).

Glaukos Accounts Payable & Accrued Expense Historical Data

* Premium members only.

The historical data trend for Glaukos's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glaukos Accounts Payable & Accrued Expense Chart

Glaukos Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable & Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 46.35 55.14 53.43 50.26 73.14

Glaukos Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 60.43 69.00 73.14 75.66 80.95
GKOS
77GF Score
Glaukos Corp GKOS
Accounts Payable & Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Glaukos Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

What does a Accounts Payable & Accrued Expense of $81.0 Mil mean?
Glaukos (GKOS) has a Accounts Payable & Accrued Expense of $81.0 Mil as of Jun. 2026. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Glaukos and its competitors.
Is Glaukos' Accounts Payable & Accrued Expense too high?
Glaukos' current Accounts Payable & Accrued Expense is $81.0 Mil. Overall, Glaukos has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Glaukos' Accounts Payable & Accrued Expense compare to BIO and GMED?
Glaukos' Accounts Payable & Accrued Expense of $81.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable & Accrued Expense for a Medical Devices & Instruments company?
A good Accounts Payable & Accrued Expense depends on the Medical Devices & Instruments industry context. However, Accounts Payable & Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable & Accrued Expense mean?
A high Accounts Payable & Accrued Expense can signal that a stock is expensive relative to its fundamentals. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Glaukos and its competitors. Glaukos's current Accounts Payable & Accrued Expense is $81.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glaukos stock overvalued right now?
Based on GuruFocus' analysis, Glaukos (GKOS) is currently considered Modestly Overvalued. The stock's GF Value™ is $151.01, compared to a current price of $180.35 — trading 19.4% above its estimated fair value. The current Accounts Payable & Accrued Expense is $81.0 Mil. Glaukos' overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable & Accrued Expense calculated?
Accounts Payable & Accrued Expense is calculated from a company's financial statements. For Glaukos (GKOS), the current Accounts Payable & Accrued Expense is $81.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Glaukos (GKOS) Overvalued in 2026?

Based on GuruFocus' analysis, Glaukos stock appears to be overvalued. The current stock price of $180.35 is trading 19.4% above its estimated GF Value™ of $151.01. GuruFocus considers Glaukos to be Modestly Overvalued.

Key valuation signals for GKOS:

  • Accounts Payable & Accrued Expense: $81.0 Mil
  • GF Value™: $151.01 vs. price of $180.35 (19.4% above fair value)
  • GF Score™: 77/100 with 6 warning signs

No single metric tells the full story. See the GKOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Glaukos Business Description

Other Exchanges 6GJ:Germany
Address One Glaukos Way, Aliso Viejo, CA, USA, 92656
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
77GF Score

Get the complete analysis for GKOS

Accounts Payable & Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$180.35
Price
$151.01
GF Value